亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Locoregional Treatment of Glioblastoma With Targeted α Therapy

医学 多塔 总体生存率 内科学 胶质母细胞瘤 不利影响 肿瘤科 核医学 癌症研究 体内 生物 生物技术
作者
Leszek Królicki,Jolanta Kunikowska,Frank Bruchertseifer,Radosław Kuliński,Dariusz Pawlak,Henryk Koziara,Rafał Rola,Alfred Morgenstern,Adrian Merlo
出处
期刊:Clinical Nuclear Medicine [Lippincott Williams & Wilkins]
卷期号:48 (5): 387-392 被引量:10
标识
DOI:10.1097/rlu.0000000000004608
摘要

Glioblastoma (GB) is the most malignant primary brain tumor. Therefore, introduction of new treatment options is critically important. The aim of this study was to assess local treatment with α emitters [ 213 Bi]Bi-DOTA-substance P (SP) and [ 225 Ac]Ac-DOTA-SP.Treatment was performed as salvage therapy in patients with recurrent primary and secondary GB. [ 213 Bi]Bi-DOTA-SP with injected activity 1.85 GBq per cycle was used in 20 primary (48.2 ± 11.8 years old) and in 9 secondary (38.8 ± 10.8 years old) GB patients and [ 225 Ac]Ac-DOTA-SP in 15 primary (45.1 ± 9.9 years old) and in 6 secondary (37.8 ± 6.4 years old) GB patients with a dose escalation scheme (10, 20, and 30 MBq).Local treatment with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP was well tolerated with only few adverse effects. There was no statistically significant difference between [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP groups in survival parameters. For primary GB, survival parameters of patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows(in months): progression-free survival time, 2.7 versus 2.4; OS-d (overall survival from time of diagnosis to death from any cause), 23.6 versus 21.0; OS-t (overall survival from the start of treatment to death from any cause), 7.5 versus 5.0; and OS-r (overall survival from recurrence in primary tumors to death from any cause), 10.9 versus 12.0. Survival parameters of secondary GB patients treated with [ 213 Bi]Bi-DOTA-SP and [ 225 Ac]Ac-DOTA-SP were as follows (in months): progression-free survival time, 5.8 versus 2.4; OS-d, 52.3 versus 65.0; OS-t, 16.4 versus 16.0; and OS-c (overall survival from conversion into secondary GB multiforme to death from any cause), 18.4 versus 36.0.The similarity results of 213 Bi or 225 Ac may suggest that the local treatment of brain tumors can be greatly simplified. The experience to date shows that local radioisotope treatment of brain tumors requires further dosimetry studies, taking into account the complexity of biological processes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xixiazhiwang完成签到 ,获得积分10
4秒前
14秒前
牧野牧发布了新的文献求助10
20秒前
小蘑菇应助科研通管家采纳,获得10
28秒前
牧野牧完成签到,获得积分10
37秒前
ljl86400完成签到,获得积分10
41秒前
43秒前
Owen应助Dingding采纳,获得10
47秒前
小jie发布了新的文献求助10
48秒前
12完成签到 ,获得积分10
58秒前
小jie完成签到,获得积分10
1分钟前
ajing完成签到,获得积分10
1分钟前
小二郎应助小jie采纳,获得10
1分钟前
OhHH完成签到 ,获得积分10
1分钟前
shier完成签到 ,获得积分10
1分钟前
1分钟前
浮游应助木子采纳,获得10
1分钟前
周炎发布了新的文献求助10
2分钟前
Chen完成签到 ,获得积分10
2分钟前
2分钟前
fft完成签到,获得积分10
2分钟前
狂野的衬衫完成签到,获得积分10
2分钟前
Dingding发布了新的文献求助10
2分钟前
dahua完成签到 ,获得积分10
2分钟前
3分钟前
程大学发布了新的文献求助10
3分钟前
Dingding关注了科研通微信公众号
3分钟前
程大学完成签到,获得积分10
3分钟前
程大学驳回了ZJX应助
3分钟前
3分钟前
思源应助fft采纳,获得10
3分钟前
yys发布了新的文献求助10
3分钟前
打打应助yys采纳,获得10
3分钟前
wearelulu完成签到,获得积分10
3分钟前
4分钟前
sjj发布了新的文献求助10
4分钟前
4分钟前
量子星尘发布了新的文献求助10
4分钟前
在水一方应助sjj采纳,获得10
4分钟前
饼干肥熊完成签到 ,获得积分10
4分钟前
高分求助中
Comprehensive Toxicology Fourth Edition 24000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Hydrothermal Circulation and Seawater Chemistry: Links and Feedbacks 1200
Pipeline and riser loss of containment 2001 - 2020 (PARLOC 2020) 1000
World Nuclear Fuel Report: Global Scenarios for Demand and Supply Availability 2025-2040 800
Handbook of Social and Emotional Learning 800
Risankizumab Versus Ustekinumab For Patients with Moderate to Severe Crohn's Disease: Results from the Phase 3B SEQUENCE Study 600
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 5148266
求助须知:如何正确求助?哪些是违规求助? 4344641
关于积分的说明 13529679
捐赠科研通 4186621
什么是DOI,文献DOI怎么找? 2295762
邀请新用户注册赠送积分活动 1296179
关于科研通互助平台的介绍 1239953